Related to this topic: Leaflets | Support | Patient+ | Weblinks | Equipment | Books | Your Experience | Other resources | Glossaries
Print options: Printer friendly version of this leaflet (html)     Other options:  AddThis Social Bookmark Button (what's this?)

PatientPlus articles are written for doctors and so the language can be technical. However, some people find that they add depth to the articles found in the other sections of this website which are written for non-medical people.

Necrotising Fasciitis

Necrotising fasciitis is an insidiously advancing soft tissue infection characterized by widespread fascial necrosis. The condition was first described in the scrotum region by Fournier in 1883 (Fournier's gangrene) and as a more generalised condition by Meleney in 1924.

Although it is most often associated with S. pyogenes (group A beta-haemolytic streptococci) infection, this accounts for a minority of cases and most infections are polymicrobial, with both anaerobic and aerobic bacteria frequently present.1,2 Organisms spread from the subcutaneous tissue along the superficial and deep fascial planes.

Epidemiology
  • Necrotising fasciitis is uncommon, but is a cause of severe morbidity and frequent mortality.
  • The incidence in the United Kingdom is estimated at 500 new cases each year.3

Risk Factors

  • In many cases, there is no association with any underlying factor.
  • May develop after skin biopsy, needle puncture sites in intravenous drug abusers and associated with chronic venous leg ulcers, open bone fractures and surgical wounds.4
  • Other predisposing factors include age over 60, malnutrition, penetrating wounds, diabetes mellitus, alcohol abuse, peripheral vascular disease, renal failure, underlying malignancy, obesity, intravenous drug misuse and immunosuppression.
  • However, approximately 50% of cases of streptococcal necrotising fasciitis occur in young, previously healthy individuals.
Presentation
  • The diagnosis is clinical. Necrotising fasciitis can affect any part of the body but the extremities, the perineum, and the truncal areas are the most commonly involved.3
  • Patients are very ill with disproportionate pain and only minor skin changes in the early phases.5
  • Tends to begin with constitutional symptoms of fever and chills.
  • Patients may present with some evidence of cellulitis, vesicles, bullae, oedema, crepitus, erythema, and fever.6
  • The degree of pain may be out of proportion to the physical findings. As the infection progresses, their pain may decrease due to nerve damage.
  • After 2-3 days, erythema and vesiculation or bullae develop.

Signs

  • From a rapidly advancing erythema, painless ulcers may appear as the infection spreads along the fascial planes.
  • A black necrotic eschar may be evident at the borders of the affected areas.
  • Metastatic cutaneous plaques.
  • In patients with diabetes, crepitus is often evident, as are non-clostridial anaerobic infections.
  • Although the following features can occur with cellulitis, they may suggest necrotising fasciitis:
    • Rapid progression and poor therapeutic response.
    • Extreme local tenderness; blistering necrosis; cyanosis.
    • High temperature, tachycardia, hypotension, altered level of consciousness.
Differential Diagnosis
Investigations
  • Blood tests: leucocytosis acidosis, altered coagulation profile, hypoalbuminaemia, abnormal renal function.3
  • X-ray: soft tissue gas.
  • One study has shown that a white cell count greater than 15.4 x 10(9)/L and serum sodium less than 135mmol/L are useful parameters that may help to distinguish necrotising from non-necrotising infection.7
  • New diagnostic techniques include rapid streptococcal diagnostic kits and a polymerase chain reaction involving SPE genes (eg, SPE-B).
  • MRI or CT delineation of the extent of infection may be useful in directing rapid surgical debridement.
  • Excisional deep skin biopsy may be helpful in diagnosing and identifying the causative organisms. Cultures of the affected tissue obtained at initial debridement may be helpful.
Management
  • Resuscitation as required, followed by aggressive early debridement of infected tissues is critical to management.3
  • The role of hyperbaric oxygen is controversial but has been shown to improve survival and limb salvage.3,8

Drugs

  • Antimicrobial therapy is important but remains secondary to the removal of diseased and necrotic tissues.
  • The choice of antibiotic(s) will depend on local guidelines and the individual situation of each patient. The choice should be discussed with the local consultant microbiologist.
  • Empirical broad-spectrum antibiotics should be administered immediately. A foul smell in the lesion strongly suggests the presence of anaerobic organisms.
  • Combination therapy: this approach involves the use of 2 or 3 antibiotics. To cover aerobes (usually gram-negative organisms), ampicillin and gentamicin are useful. For anaerobes, clindamycin or metronidazole has been used. In group A streptococcal infections, clindamycin has been used, specifically in combination with beta-lactam antibiotics.
  • Single antibiotic: broad-spectrum beta-lactam drugs such as imipenem cover aerobes, including Pseudomonas species. Ampicillin also has broad-spectrum coverage, but it does not cover Pseudomonas species. The maximum doses of the antibiotics should be used. Once culture and sensitivity results are available, the antibiotic coverage should be reviewed.
Complications
  • Deep infection causes vascular occlusion, ischaemia and tissue necrosis. Superficial nerves are damaged, causing local anaesthesia. Infection then spreads to septicaemia, which leads to severe systemic toxicity and rapid death unless appropriately treated.
  • Streptococcal exotoxin production may lead to toxic shock with fever, rash, hypotension, multiorgan involvement (e.g. cardiomyopathy, renal failure, encephalopathy, hepatic necrosis) and desquamation of the skin of the palms and soles.
  • Metastatic cutaneous plaques may occur.
Prognosis
  • These infections must be detected and treated rapidly to prevent loss of limb or a fatal outcome.
  • Estimates of mortality rate vary from 6-76% but recent studies suggest a mortality rate in the region of 25%.39
  • Increased mortality is associated with delays in diagnosis, poor surgical technique and diabetes.10

Document References
  1. Schwartz RA; Necrotizing Fasciitis; eMedicine July 2006.
  2. Elliott D, Kufera JA, Myers RA; The microbiology of necrotizing soft tissue infections. Am J Surg. 2000 May;179(5):361-6. [abstract]
  3. Hasham S, Matteucci P, Stanley PR, et al; Necrotising fasciitis. BMJ. 2005 Apr 9;330(7495):830-3.
  4. Bosshardt TL, Henderson VJ, Organ CH Jr; Necrotizing soft-tissue infections. Arch Surg. 1996 Aug;131(8):846-52; discussion 852-4. [abstract]
  5. Burge TS, Watson JD; Necrotising fasciitis. BMJ 1994;308:1453-1454 (4 June).
  6. Headley AJ; Necrotizing soft tissue infections: a primary care review. Am Fam Physician. 2003 Jul 15;68(2):323-8. [abstract]
  7. Wall DB, Klein SR, Black S, et al; A simple model to help distinguish necrotizing fasciitis from nonnecrotizing soft tissue infection. J Am Coll Surg. 2000 Sep;191(3):227-31. [abstract]
  8. Wilkinson D, Doolette D; Hyperbaric oxygen treatment and survival from necrotizing soft tissue infection. Arch Surg. 2004 Dec;139(12):1339-45. [abstract]
  9. Urschel JD; Necrotizing soft tissue infections. Postgrad Med J. 1999 Nov;75(889):645-9. [abstract]
  10. Ward RG, Walsh MS; Necrotizing fasciitis: 10 years' experience in a district general hospital. Br J Surg. 1991 Apr;78(4):488-9. [abstract]
Acknowledgements EMIS is grateful to Dr Colin Tidy for writing this article. The final copy has passed scrutiny by the independent Mentor GP reviewing team. ©EMIS 2007.
DocID: 2495
Document Version: 21
DocRef: bgp231
Last Updated: 22 Dec 2006
Review Date: 21 Dec 2008




















Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.

Advertise on this site










Disclaimer: Patient UK has no control of the content of the above links. Inclusion does not imply endorsement by Patient UK.

Advertise on this site


PS - Health and Poverty

Perhaps the biggest cause of ill health in the world is poverty. Help to Make Poverty History. For example, why not lend some of your money to disadvantaged communities to enable them to trade their way out of poverty through schemes such as Shared Interest.

See also MAKEPOVERTYHISTORY North East for details and links to campaigns against poverty.

^ Top of Page